Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07203001 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
A Phase 2 study of Still´s Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 20
- Study locations
NCT07203001: Recruiting Phase 2 study of Still´s Disease, sponsored by Novartis Pharmaceuticals.
NCT07203001 is a Phase 2 study of Still´s Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07203001, a Phase 2 study of Still´s Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease
Primary Outcome
Established measure for efficacy of treatments in the rheumatologic conditions taking into account self-assessment, function and survival.
Conditions Studied
Interventions
- DRUG MAS825
Study Locations (20)
Other
- Novartis Investigative Site - Bordeaux
- Novartis Investigative Site - Le Kremlin-Bicêtre
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Münster
- Novartis Investigative Site - Utrecht
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Valencia
Quebec
- Novartis Investigative Site - Montreal
- Novartis Investigative Site - Montreal
Ohio
- Cincinnati Childrens Hospital - Cincinnati
Oregon
- Legacy Emanuel Research Hosp Portland - Portland
North Rhine-Westphalia
- Novartis Investigative Site - Sankt Augustin
FI
- Novartis Investigative Site - Florence
GE
- Novartis Investigative Site - Genova
RM
- Novartis Investigative Site - Roma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2029-05-24 |
| Phase | Phase 2 |
What NCT07203001 shows while recruiting
NCT07203001 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Still´s Disease appearing as the primary indexed condition, and to 1 intervention - of which MAS825 is the first listed.
NCT07203001 names 20 study sites across 11 states, led by Other, Quebec, Ohio.
Frequently Asked Questions
What is clinical trial NCT07203001 about?
NCT07203001 is a clinical study titled "A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease". The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease
What is the current status of trial NCT07203001?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-11-03. Estimated completion is 2029-05-24.
What conditions does trial NCT07203001 study?
This clinical trial studies the following conditions: Still´s Disease.
What interventions are being tested in trial NCT07203001?
The interventions under investigation include: MAS825 (DRUG).
Who is sponsoring clinical trial NCT07203001?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07203001 being conducted?
This trial has 20 study locations across Ohio, Oregon, Quebec, North Rhine-Westphalia, FI. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07203001's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI